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This issue of the European Respiratory Review (ERR) includes selected articles from the 7th International
Meeting on Pulmonary Rare Diseases and Orphan Drugs [1–8], as well as a Frontiers in Clinical Practice
article addressing the rare disease pulmonary Langerhans cell histiocytosis (PLCH) [9].
Since its first edition in 2005, the International Meeting on Pulmonary Rare Diseases and Orphan Drugs
has been held every 2 years, with the most recent meeting taking place in Milan (Italy) in February 2017.
The conference, endorsed by the European Respiratory Society (ERS), is the only European meeting
dedicated to the different types of rare parenchymal and vascular pulmonary diseases (see [10] for more
information and slide presentations). The success of the congress is based on the many topics discussed
(translational and clinical), which bring together scientists from different fields of expertise (pulmonary
hypertension (PH), lymphangioleiomyomatosis (LAM), idiopathic pulmonary fibrosis (IPF), etc.) and offer
them the unique opportunity to gain insight into a broad range of subjects within the area of respiratory
medicine. The international scientific committee, composed of leading representatives of the medical
community in Europe and the USA, suggested the topics to be included in the scientific programme. In
2017, the committee included Yochai Adir (Israel), Katerina Antoniou (Greece), Harold Collard (USA),
Marc Humbert (France), Joel Moss (USA), Venerino Poletti (Italy), Ganesh Raghu (USA), Gérald
Simonneau (France), Carlo Vancheri (Italy), Athol Wells (UK) and Sergio Harari (Italy, Congress Chair).
As for past editions of the meeting, when selected articles were published in the ERR (for editorials, see
[11–13]), the current issue of the ERR contains articles based on some presentations from the 7th meeting,
to affirm the engagement of the ERR in this area and more generally account for the space devoted by all
ERS publications to rare diseases and orphan drugs as well as rare conditions linked to the most frequent
pathologies (severe asthma, rare thoracic cancers and others), which share with rare diseases some aspects
of research and methodology [11, 14].
Over the past 25 years, the interest in rare diseases in the international scientific community and especially
in the respiratory area has grown remarkably. The flag of this paradigm shift is certainly carried by
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pulmonary arterial hypertension, a disease that has achieved very important milestones in translational
research and in treatment modalities [15]. The data clearly demonstrate the important research movement
that has accompanied rare respiratory diseases in recent years. Here are some examples: 1) from 1990 to
2010, there were only four clinical trials about LAM published on PubMed, while between January 1, 2010
and April 30, 2017, the number of papers on clinical trials increased to 17; 2) 33 papers carried out on
IPF trials were published in the decade 1990–2000, 60 the following decade and 116 in the last 7 years;
and 3) the number of clinical trials on PH and non-cystic fibrosis bronchiectasis has recently increased
very significantly (table 1). These amazing advances are clear evidence of the great work already
accomplished and that which is still in progress.
Another very interesting advance is the implementation of the European Network of Reference Centres for
Rare Lung Diseases within the framework of the 24 European Reference Networks (ERNs) approved in
December 2016 by the European Commission’s Board of Member States (https://ec.europa.eu/health/ern/
networks_en). ERN-LUNG is a network of healthcare providers dedicated to the care and investigation of
patients suffering from rare respiratory diseases [16], which we believe can represent an important scientific
support structure in the future. As a matter of fact and as already pointed out in one of our previous
editorials [14], it is also important to identify uniform criteria for adoption by referral centres in the
various European countries in the spirit of the “free circulation of patients within the European member
states”. In selected cases, it will also be crucial to establish dedicated European referral centres and networks
capable of properly managing patients and therefore in a position to accumulate enough experience so as to
maximise the necessary skills required in the management of particularly rare diseases [14].
In this issue of the ERR, a group of articles are published that provide an overview of important topics in
pulmonary medicine. GIRERD et al. [1] propose an excellent and very useful overview of the complex issues
related to genetic counselling in PH, issues which are common to other rare lung diseases and therefore of
current great interest. LAUNAY et al. [2] deal with the different expressions of PH in scleroderma and their
clinical profiles. RUBBO and LUCAS [3] offer a comprehensive and thorough overview of primary ciliary
dyskinesia and the related diagnostic and therapeutic aspects. TORRE et al. [4] explore the latest novelties in
LAM and PLCH, both in terms of research, genetics and therapy. MILANI et al. [5] tackle the subject of a
little known but clinically relevant condition, lung involvement in amyloidosis, with regards to the possible
clinical consequences for the affected patients. TORRISI et al. [6] take on the difficult task of exploring the
indications and contraindications of antifibrotic therapies in IPF, a topical issue of great relevance, while
CAMINATI et al. [7] discuss how to deal with the most advanced phases of this disease. Finally, RAGHU [8], a
worldwide expert on IPF and other interstitial lung diseases, discusses the future landscapes for the
treatment of IPF and analyses the most important and promising trials in the pharmacological therapy of
this disease.
Moreover, also in the current issue of the ERR, LORILLON and TAZI [9] illustrate the current management of
PLCH. Abdellatif Tazi is the leader of the French national reference centre for Langerhans cell
histiocytosis, and this Frontiers in Clinical Practice article describes several clinical cases as well as key
features of PLCH.
The ERR is once again delighted to publish important contributions coming from the prestigious 7th
International Meeting on Pulmonary Rare Diseases and Orphan Drugs, emphasising that rare diseases do
represent a major field of medicine, not only for pulmonologists expert in rare pulmonary diseases, but for
all respiratory physicians, as well as specialists from associated fields with whom we work on a daily basis
in our clinical settings. This fully reflects the scientific spirit of the ERR and its editorial line [17].
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